Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flurbiprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 1.00 |
| ▸ | PTGS2 known ✓ | P35354 | 3/20 | 1.00 |
| ▸ | AKR1C3 | P42330 | 11/20 | 1.00 |
| ▸ | AKR1C2 | P52895 | 11/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | FABP2 | P12104 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | AKR1C4 | P17516 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tarenflurbil SCHEMBL26131 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Esflurbiprofen SCHEMBL505817 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL1070292 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Tarenflurbil SCHEMBL29350102 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754830 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8754978 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL2248 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL8755275 | 1.00 | AKR1C3 (1.00) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL3519037 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 | |
| Flurbiprofen SCHEMBL9877586 | 0.98 | AKR1C3 (0.97) | AKR1C3AKR1C2PTGS1PTGS2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 703 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018048-A1 | FLUCONAZOLE-COX INHIBITOR HYBRIDS: A DUAL-ACTING CLASS OF ANTIFUNGAL AZOLES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-01-16 | — | — | US | claimed |
| US-20250017846-A1 | TOPICAL ANALGESICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-01-16 | — | — | US | claimed |
| WO-2024133913-A2 | SEMIFLUORINATED ALKANE COMPOSITIONS COMPRISING HYOSCYAMINE | NOVALIQ GMBH (DE) | 2024-06-27 | — | — | WO | claimed |
| CN-118125916-A | S- (+) -flurbiprofen salt and preparation method, pharmaceutical composition and application thereof | 南京知和医药科技有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117982420-A | S (+) -flurbiprofen axetil emulsion for injection and preparation method thereof | 西藏珠峰寿高生物药业有限公司 | 2024-05-07 | — | — | CN | claimed |
| CN-115536525-B | S- (+) -flurbiprofen salt and preparation method, pharmaceutical composition and application thereof | 南京知和医药科技有限公司 | 2024-02-23 | — | — | CN | claimed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | claimed |
| CN-115768146-A | Efficient perovskite solar cell regulated and controlled by chiral molecules and preparation method thereof | 河北工业大学 | 2023-03-07 | — | — | CN | claimed |
| CN-115536525-A | S- (+) -flurbiprofen salt and preparation method, pharmaceutical composition and application thereof | 南京知和医药科技有限公司 | 2022-12-30 | — | — | CN | claimed |
| CN-115484984-A | Method for improving stability of pharmaceutical composition comprising high penetration drug and pharmaceutical composition obtained thereby | 于崇曦 | 2022-12-16 | — | — | CN | claimed |
| EP-0103265-B1 | BIPHENYLYLPROPIONIC ACID DERIVATIVE, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1986-12-03 | — | — | EP | claimed |
| EP-0078709-B1 | PREPARATION OF NITROARALKYL CYANIDES AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1986-10-01 | — | — | EP | claimed |
| EP-0077662-B1 | PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1985-10-02 | — | — | EP | claimed |
| EP-0130514-A2 | Depot antiphlogistics | Troponwerke GmbH & Co. KG (DE) | 1985-01-09 | — | — | EP | claimed |
| US-4489080-A | SYNERGISTIC COMBINATION OF NARCOTIC AND FLURBIPROFEN OR ESTER | THE UPJOHN COMPANY (US) | 1984-12-18 | — | — | US | claimed |
| US-4379091-A | Esters of arylpropionic acids endowed with an anti-inflammatory activity | AUSONIA FARMACEUTICI S.R.L. (IT) | 1983-04-05 | — | — | US | claimed |
| EP-0017169-B1 | IMPROVED ANTI-INFLAMMATORY COMBINATIONS HAVING REDUCED ULCEROGENICITY | MERCK & CO. INC. (US) | 1983-03-09 | — | — | EP | claimed |
| EP-0070714-A1 | Use of ibuprofen or flurbiprofen for the manufacture of a medicament for treating respiratory disorders | THE UPJOHN COMPANY (US) | 1983-01-26 | — | — | EP | claimed |
| US-4309421-A | Stabilized parenterally administrable solutions | A. NATTERMANN & CIE. GMBH (DE) | 1982-01-05 | — | — | US | claimed |
| EP-0017169-A1 | Improved anti-inflammatory combinations having reduced ulcerogenicity | MERCK & CO. INC. (US) | 1980-10-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017846-A1 | TOPICAL ANALGESICS | OPRK1, OPRL1, OPRM1 | PTGS1 113/4885PTGS2 127/4885AKR1C3 1383/4885 |
| US-20250018048-A1 | FLUCONAZOLE-COX INHIBITOR HYBRIDS: A DUAL-ACTING CLASS OF ANTIFUNGAL AZOLES | PTGS2, PTGIS, CYP2E1 | PTGS1 4/4885PTGS2 1/4885AKR1C3 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.